Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
|
|
Sienna Biopharmaceuticals, Inc. (SNNA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/14/2019 |
GN
| Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice |
| 06/20/2019 |
GN
| Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference |
| 06/10/2019 |
GN
| Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology |
| 05/21/2019 |
GN
| Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe |
| 05/14/2019 |
GN
| Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis |
| 05/09/2019 |
GN
| Sienna Biopharmaceuticals to Present at BAML Health Care Conference |
| 03/21/2019 |
GN
| Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations |
| 03/14/2019 |
GN
| Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results |
| 03/05/2019 |
GN
| Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference |
| 02/20/2019 |
GN
| Sienna Biopharmaceuticals Prices Public Offering of Common Stock |
| 02/19/2019 |
GN
| Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock |
| 02/08/2019 |
GN
| Sienna Biopharmaceuticals' Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System |
| 01/02/2019 |
GN
| Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference |
| 12/06/2018 |
GN
| Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference |
| 12/03/2018 |
GN
| Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019 |
| 11/13/2018 |
GN
| Detailed Research: Economic Perspectives on Pernix Therapeutics, Hallador Energy, Vince Holding, Tuesday Morning, Information Services Group, and Sienna Biopharmaceuticals — What Drives Growth in Today's Competitive Landscape |
| 08/27/2018 |
GN
| Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2 |
| 08/09/2018 |
GN
| Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results |
| 08/02/2018 |
GN
| Sienna Biopharmaceuticals Appoints Finance Veteran, James M. Hindman, to Board of Directors |
| 07/30/2018 |
GN
| Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints |
| 07/24/2018 |
GN
| Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis |
| 07/02/2018 |
GN
| Sienna Biopharmaceuticals Enters $40 Million Term Loan Agreement |
| 06/14/2018 |
GN
| Sienna Biopharmaceuticals to Present at JMP Securities Life Science Conference |
| 05/31/2018 |
GN
| Sienna Biopharmaceuticals to Present at Jefferies Healthcare Conference |
| 05/14/2018 |
GN
| Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results |
| 05/11/2018 |
GN
| Sienna Biopharmaceuticals to Present at BAML Health Care Conference |
| 03/22/2018 |
GN
| Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer |
| 03/21/2018 |
GN
| Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer |
| 03/15/2018 |
GN
| Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results |
| 03/12/2018 |
GN
| Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis |
| 03/06/2018 |
GN
| Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference |
| 02/14/2018 |
GN
| Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125 |
| 01/04/2018 |
GN
| Sienna Biopharmaceuticals to Present at J.P. Morgan Healthcare Conference |
| 12/12/2017 |
GN
| Sienna Biopharmaceuticals Establishes Corporate Advisory Board |
|
|